Moderna's mRNA Vaccines vs. Neoantigen Therapies: Navigating the Gray Area of Terminology and Public Perception
Original framing: “What’s in a name? Moderna’s “vaccine” vs. “therapy” dilemma” — MIT Technology Review
The development of mRNA vaccines is part of a longer history of vaccine development that dates back to the 18th century. Understanding the historical context of vaccine development is crucial for appreciating the complexities of public perception and the need for nuanced communication.
The debate over whether Moderna's mRNA vaccines should be referred to as 'vaccines' or 'therapies' highlights the complexities of public perception and the need for nuanced communication.
To effectively navigate this gray area, we must develop more culturally sensitive vaccine communication strategies, incorporate indigenous knowledge into vaccine development, and develop more holistic and effective vaccine strategies. By doing so, we can promote more inclusive and equitable vaccine development and deployment, and ultimately improve public health outcomes.